ERC-1671 is under clinical development by ERC Belgium and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II drugs for Gliosarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ERC-1671 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ERC-1671 overview
ERC-1671 (Gliovac) vaccine is under development for the prevention of recurrent glioblastoma multiforme and gliosarcoma. It is administered through intradermal route. Vaccine candidate is composed of a combination of autologous and allogeneic glioblastoma (GBM) tumor cells derived from GBM cancer patients.
ERC Belgium overview
ERC Belgium is a clinical stage biopharmaceutical company that research for generic cell therapy treatments. The company’s pipeline product include Gliovac-ERC1671, a therapeutic anti-glioblastoma vaccine that contains allogeneic and autologous tumor cells that is used for the treatment of glioblastoma multiforme. ERC Belgium products is used to treats patients diagnosed with grade IV glioma (glioblastoma multiforme and gliosarcoma), when other traditional treatments have failed. The company markets its products throughout Belgium, the Netherlands, the US, Canada and Australia. ERC Belgium is headquartered in Namur, Belgium.
For a complete picture of ERC-1671’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
